

NATH SEEDS®

## **Nath Bio-Genes (I) Ltd.**

(CIN L01110MH1993PLC072842)

Date: 28.10.2017

1. The Secretary,  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, MUMBAI 400 001

2. The Secretary,  
National Stock Exchange of India Ltd  
Exchange Plaza, 5th Floor  
Plot No. C/1, G Block  
Bandra-Kurla Complex  
Bandra (E), MUMBAI 400 051

Company Code: 537291

Sub: Submission of information under regulation 33 (3) (a) of the SEBI (LODR) Regulations , 2015.

Dear Sir,

Please find enclosed herewith Quarterly unaudited Financial Results for the quarter ended 30<sup>th</sup> September 2017.

The above information is being provided to you under Regulation 33 (3) (a) of The SEBI (LODR) Regulations, 2015.

This is for your information and record purpose.

Thanking You.

Yours Faithfully,  
For Nath Bio Genes (India) Limited

Authorized Signatory

**ASHOK R. MAJETHIA**

BCom. F.C.A  
CHARTERED ACCOUNTANT

Ashok R. Majethia & Co.  
Chartered Accountants  
Utsav Complex,  
Office No. 7, Bazar Peth,  
Dist. Raigad, Khopoli – 410 203  
Tel :- (02192) 269908  
Mobile :- 9404711539 / 9372169952  
Email :- ashokmajethia@redifmail.com

### LIMITED REVIEW REPORT

To

The Board of Directors of  
Nath Bio-genes (India) Limited

1. We have reviewed the accompanying statement of unaudited financial results for the quarter ended 30<sup>th</sup> September, 2017 (the Statement) of NATH BIO-GENES (INDIA) LIMITED (the Company). This statement has been prepared by the Company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 (the "Listing Regulation, 2015" read with SEBI circular dated July 05, 2016 which has been initialed by us for identification purposes.

The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Further, the management is also responsible to ensure that Company's Accounting Policies used in preparation of this statement are consistent with those used in the preparation of companies opening unaudited balance Sheet as at 1<sup>st</sup> April 2017 prepared in accountance with Companies (Ind-AS) Rules 2015 prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the statements based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement.

3. A review is limited primarily to enquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement has not been prepared in all material respect in accordance with Ind-AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of regulation 33 of the Listing Regulations, 2015 read with SEBI Circular dated 5<sup>th</sup> July 2015 including the manner in which it is to be disclosed, or that it contains any material mis-statement.

For Ashok R. Majethia & Co.  
Chartered Accountants  
(Registration No. 127768)

Ashok R. Majethia  
Proprietor  
M.No. 124781



Place: Aurangabad  
Date: 28.10.2017



**Nath Bio-Genes (I) Ltd.**

(CIN L0110MH1993PLC02342)

	2017	2016	2015	2014	2013	2012
<b>I Income From Operations</b>						
(a) Net Sales / Income from operations	1439.14	10149.65	1645.30	11588.79	10078.29	16972.56
(b) Other Operating Income	4.53	5.35	15.13	9.88	27.11	65.91
<b>Total income from Operations</b>	<b>1443.67</b>	<b>10155.00</b>	<b>1660.44</b>	<b>11598.67</b>	<b>10105.40</b>	<b>17038.47</b>
<b>II Expenses</b>						
a) Cost of Material Consumed	289.11	1569.88	1410.79	1858.99	3392.24	5845.98
b) Purchase of Stock-in-Trade	0.00	18.43	0.00	18.43	0.00	196.52
c) Changes in Inventory	(3.26)	3761.44	(787.01)	3758.18	977.60	1040.42
d) Employee benefit expense	382.62	-383.65	387.94	766.27	831.72	1373.61
e) Finance Cost	267.32	285.40	175.31	552.72	409.59	965.71
f) Depreciation & Amortisation	25.00	25.00	241.57	50.00	175.34	303.04
g) Selling & Distribution Expenses	72.95	1758.19	75.34	1831.14	2304.60	3903.67
h) Other Expenditure	49.68	321.31	76.59	370.99	284.91	1727.25
<b>Total Expenses</b>	<b>1083.43</b>	<b>8123.29</b>	<b>1580.53</b>	<b>9206.72</b>	<b>8376.00</b>	<b>15356.19</b>
<b>III Profit / (Loss) before Exceptional Items &amp; Tax (I - II)</b>	<b>360.25</b>	<b>2031.70</b>	<b>79.91</b>	<b>2391.95</b>	<b>1729.40</b>	<b>1682.28</b>
<b>IV Exceptional Items Income/(Expenses)</b>	<b>0.00</b>	<b>(13.86)</b>	<b>0.08</b>	<b>(13.86)</b>	<b>0.08</b>	<b>6.94</b>
<b>V Profit / (Loss) before Tax (III-IV)</b>	<b>360.25</b>	<b>2045.56</b>	<b>79.83</b>	<b>2405.81</b>	<b>1729.32</b>	<b>1675.34</b>
<b>VI Tax expense</b>	<b>4.62</b>	<b>28.05</b>	<b>0.00</b>	<b>32.67</b>	<b>0.00</b>	<b>47.10</b>
<b>VII Net Profit / (Loss) for the period (V-VI)</b>	<b>355.63</b>	<b>2017.51</b>	<b>79.83</b>	<b>2373.14</b>	<b>1729.32</b>	<b>1628.25</b>
<b>VIII Other Comprehensive Income (Items that will not be classified to Profit &amp; Loss)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>IX Total Comprehensive Income for the period (VII + VIII)</b>	<b>355.63</b>	<b>2017.51</b>	<b>79.83</b>	<b>2373.14</b>	<b>1729.32</b>	<b>1628.25</b>
<b>X Paid Up Equity Share Capital (Face Value Rs. 10/- each)</b>	<b>1600.40</b>	<b>1600.40</b>	<b>1600.40</b>	<b>1600.40</b>	<b>1600.40</b>	<b>1600.40</b>
<b>XI Reserves (excluding Revaluation Reserves) as per balance sheet of</b>	<b>14531.38</b>	<b>14175.75</b>	<b>12259.32</b>	<b>14531.38</b>	<b>12259.32</b>	<b>12158.24</b>
<b>XII Earning per share (of Rs 10/- each) (not annualised) Basic &amp; Diluted</b>	<b>2.22</b>	<b>12.61</b>	<b>0.50</b>	<b>14.83</b>	<b>10.81</b>	<b>10.17</b>

**NOTES:**

- (1) Above financial results are taken on record by the Board of Directors in their meeting held on 28th October 2017.
- (2) The company is constantly improving its Product Mix for better profits and launching new research products in various crops
- (3) The company is dealing in one major product segment, i.e. Seed Cultivation
- (4) The Company has commenced accounting as per IAS from 1 Apr 2017.
- (5) Investor complaints - Opening Balance - 0, Received and Solved - 1, Closing Balance - 0

FOR NATH BIO-GENES (INDIA) LTD

Place : Aurangabad


Date : 28th October 2017

*(Signature)*  
Satish Kagiwal  
MANAGING DIRECTOR  
DIN 00119601

Regd. Office : Nath House, Nath Road, Aurangabad - 431005 (MS)  
www.nathbiogenes.com


For Ashok R. Majethia & Co.  
Chartered Accountants  
(Registration No. 127768)

Ashok R. Majethia  
Proprietor  
M.No. 124781



Nath Bio-Genes (India) Limited  
Standalone Statement of Assets and Liabilities

Rs. In Lacs

Particulars	As at quarter end 30.09.2017	As at previous year end 31.03.2017
	(Unaudited)	(Audited)
<b>A EQUITIES AND LIABILITIES</b>		
1. Shareholders' Fund		
(a) Share capital	1600.40	1600.40
(b) Reserves and Surplus	14534.49	12158.24
(c) Money received against share warrants	0.00	0.00
<b>Sub-total - Shareholders' Fund</b>	<b>16134.89</b>	<b>13758.64</b>
2. Share application money pending for allotment	0.00	0.00
3. Minotiries Interest	0.00	0.00
4. Non-current liabilities		
a) Long Term Borrowings	1788.94	2006.71
b) Deferred Tax Liabilities	0.00	0.00
c) Other Long Term Liabilities	0.00	0.00
d) Long Term Provisions	220.65	200.65
<b>Sub-total - Non-current liabilities</b>	<b>2009.59</b>	<b>2207.36</b>
5. Current Liabilities		
a) Short Term Borrowings	5434.71	4860.88
b) Trade Payables	3675.21	4435.28
c) Other Current Liabilities	2028.27	3418.67
d) Short Term Provisions	287.25	254.59
<b>Sub-total - Current liabilities</b>	<b>11425.44</b>	<b>12969.42</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>29569.92</b>	<b>28935.42</b>
<b>B ASSETS</b>		
(1) Non Current Assets		
a) Fixed Assets	4117.61	4156.59
b) Non Current Investments	499.69	499.68
c) Deferred Tax Assets (Net)	85.41	85.41
d) Long Term Loans and Advances	0.00	0.00
e) Other Non Current Assets	0.00	0.00
<b>Sub-total - Non Current Assets</b>	<b>4702.71</b>	<b>4741.68</b>
(2) Current Assets		
a) Current Investments	0.00	0.00
b) Inventories	10620.50	13015.09
c) Trade Receivables	7380.09	5182.46
d) Cash and Cash Equivalents	305.63	584.70
e) Short Term Loans and Advances	6455.15	5308.44
f) Other Current Assets	105.84	103.06
<b>Sub-total - Current Assets</b>	<b>24867.21</b>	<b>24193.75</b>
<b>TOTAL ASSETS</b>	<b>29569.92</b>	<b>28935.42</b>
	0.00	0.00
FOR NATH BIO-GENES (INDIA) LTD		
		 Satish Kagiwal MANAGING DIRECTOR DIN 00119601
Place : Aurangabad		
Date : 28 October 2017		

For Ashok R. Majethia & Co.  
Chartered Accountants  
(Registration No. 127769)

Ashok R. Majethia  
Proprietor  
M.No. 124781

